BREAKING NEWS
FDA Bans Candy- and Fruit-Flavored Cigarettes
The FDA announced today that, effective immediately, cigarettes with certain flavors such as candy, fruit, and clove are now illegal in the United States. Flavored cigarettes are a gateway for many young people to become regular smokers, the agency said, and the ban, authorized by the new Family Smoking Prevention and Tobacco Control Act, aims to reduce the number of children who start smoking.
NEWS
Modified Chemo Regimen Effective in Advanced Ovarian Cancer
Women with advanced ovarian cancer lived longer and without their tumors growing after receiving a modified regimen of a standard chemotherapy drug combination, Japanese researchers reported last week. In a large phase III clinical trial, women who received carboplatin every 3 weeks and a reduced dose of paclitaxel (Taxol) once a week for 3 weeks instead of carboplatin and a higher single dose of paclitaxel every 3 weeks had a 29 percent improvement in progression-free survival and a 25 percent improvement in overall survival after 3 years of follow-up. The results were published online September 18 in The Lancet. Read more > >
Diabetes Drug Metformin Shows Promise as a Breast Cancer Treatment
Commonly used drug targets cancer stem cells in mice and will be tested in a large clinical trialHormone Therapy Linked to Risk of Death from Lung Cancer
Risk should be considered by women weighing this treatment, researchers sayRecently Discovered Virus Linked to Aggressive Prostate Tumors
Investigators are now asking whether the virus causes cancerFat Cells Interfere with Chemotherapy for Leukemia
Interactions may contribute to poorer prognosis of obese patientsHepatitis B Vaccine Lowers Risk of Liver Cancer
Immunization extends protection against hepatocellular carcinoma beyond childhood and into young adulthood
COMMENTARY
Director's Update: Using ARRA Funds to Advance Cancer Research
As the fiscal year draws to a close September 30, a number of offices around NCI become especially busy places. Members of our staff who supervise budget issues, grant funding, program management, and contract administration put in long hours, making sure every dollar is appropriately allocated. In 2009, end-of-year responsibilities are even greater, as NCI also works to distribute $1.26 billion it received under the American Recovery and Reinvestment Act (ARRA). Read more > >
| Subscribe Now! |
IN DEPTH
Charting the Path from Infection to Cancer
Researchers are trying to understand how genes and environment may play a role
Harnessing the Biological Activity of Natural Products
Controlled drug interactions may increase the effect of chemotherapy
Profiles in Cancer Research: Dr. Jun S. Wei
The NCI microbiologist reflects on his journey into oncogenomics
Featured Clinical Trial: Comparing Drug Regimens for Diffuse Large B-cell Lymphoma
Will the EPOCH-R drug regimen improve outcomes over standard R-CHOP?
UPDATES
FDA Update
- FDA Clears Test for Ovarian Cancer that Could Guide Surgical Decisions
- Committees Recommend FDA Approve Cervarix and Gardasil
Notes
- Dr. Ming Lei Named Cancer Training Branch Chief
- Dr. Louise Brinton Receives Lilienfeld Award
- Webcast Registration Available for DCIS Conference
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
